临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1025967-78-5

Lifitegrast

中文名称:立他司特
CAS号:1025967-78-5
分子式: C29H24Cl2N2O7S 分子量: 615.48
产品形式: free base
研发状态: Withdrawn
研发用途: Dry Eye Disease
研究机构: Novartis Pharmaceuticals; Novartis
研发日期: July 31 2023
研发阶段: --
Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.

CAS: 1025720-94-8

BMS-777607

中文名称:N-[4-[(2-氨基-3-氯吡啶-4-基)氧基]-3-氟苯基]-4-乙氧基-1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3-甲酰胺
CAS号:1025720-94-8
分子式: C25H19ClF2N4O4 分子量: 512.89
产品形式: free base
研发状态: Completed
研发用途: Malignant Solid Tumour
研究机构: ASLAN Pharmaceuticals
研发日期: Oct-12
研发阶段: Phase 1
BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.

CAS: 1025687-58-4

Fostamatinib (R788) disodium

CAS号:1025687-58-4
分子式: C23H24FN6O9P.2Na 分子量: 624.42
产品形式: Sodium Salt
研发状态: Not yet recruiting
研发用途: Sickle Cell Disease; Hb-SS Disease; Hemoglobin S; Disease Sickle Cell Anemia; Sickle Cell Disorders; Hemoglobin Beta Thalassemia Disease
研究机构: National Heart Lung and Blood Institute (NHLBI); National Institutes of Health Clinical Center (CC)
研发日期: May 15 2024
研发阶段: Phase 1
Fostamatinib disodium (R788, Tamatinib Fosdium), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.

CAS: 10238-21-8

Glyburide (Glibenclamide)

中文名称:格列苯脲
CAS号:10238-21-8
分子式: C23H28ClN3O5S 分子量: 494.00
产品形式: free base
研发状态: Recruiting
研发用途: Acute Spinal Cord Injury
研究机构: University of Kentucky
研发日期: July 7 2022
研发阶段: Phase 1
Glyburide (Glibenclamide) is a known blocker of vascular ATP-sensitive K+ channels (KATP), used in the treatment of type 2 diabetes.

CAS: 1020315-31-4

PF-04457845

中文名称:N-哒嗪-3-基-4-(3-{[5-(三氟甲基)吡啶-2-基]醚}苯亚甲基丙酮)哌啶-1-羧酰胺
CAS号:1020315-31-4
分子式: C23H20F3N5O2 分子量: 455.43
产品形式: Free Base
研发状态: Completed
研发用途: Healthy; Sleep
研究机构: Pfizer
研发日期: Apr-10
研发阶段: Phase 1
PF-04457845 (PF-4457845) is a potent, favorable selective inhibitor of Fatty acid amide hydrolase (FAAH) with IC50 of 7.2 nM and 7.4 nM for hFAAH and rFAAH, respectively. PF-04457845 covalently modifies the active-site serine nucleophile of FAAH with exquisite selectivity relative to other members of the serine hydrolase superfamily.

CAS: 1020172-07-9

Rebastinib (DCC-2036)

中文名称:N-[3-叔丁基-1-(喹啉-6-基)-1H-吡唑-5-基]-N'-[2-氟-4-[(2-(甲基氨基甲酰基)吡啶-4-基)氧]苯基]脲
CAS号:1020172-07-9
分子式: C30H28FN7O3 分子量: 553.59
产品形式: free base
研发状态: Completed
研发用途: Locally Advanced or Metastatic Solid Tumor
研究机构: Deciphera Pharmaceuticals LLC
研发日期: January 2 2019
研发阶段: Phase 1 : Phase 2
Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.